NLS Novo Nordisk

Novo Nordisk  announced the launch of the Community Health Collaborative, a new initiative to support and expand healthy lifestyle programming in the Trenton, New Jersey area. The Community Health Collaborative provides grants to local 501c3 organizations pursuing innovative, community-based approaches to improving urban health and wellness. The program’s launch comes off the findings of an […]

Novo Nordisk announced a new analysis of phase 3 data demonstrating people with hemophilia A who had the highest annualized bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment. Data for the recombinant factor VIII (rFVIII) product NovoEight®were presented at the 56th Annual Meeting of the […]

Novo Nordisk A/S has agreed to pay $19 million to settle a putative class action in Michigan federal court accusing it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against generic-drug makers. In an unopposed motion Tuesday for an award of attorneys’ fees, reimbursement of expenses and […]

This week Novo Nordisk launched NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue specifically designed for insulin pumps, according to the company web site. This new treatment solution, which contains NovoRapid® (insulin aspart) – a rapid-acting insulin from Novo Nordisk – is expected to make insulin pump therapy more convenient for people with diabetes […]

The obesity research unit will be co-located with the Novo Nordisk type 1 diabetes research unit at the company’s research centre in Seattle, which opened in 2009. The new unit is a result of Novo Nordisk’s increasing focus on treatment of obesity with the aim to identify novel approaches and targets for obesity treatments while increasing […]

Danish Novo Nordisk has reached a settlement with the American sales company Rocheset Drug regarding the diabetes substance Prandin. Novo Nordisk has agreed to pay USD 19 million according to the agreement. The reason behind the disagreement is a lawsuit from Rocheset Drug in January 2014. The American sales company demanded compensation for lost sales […]